Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

LEXINGTON, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that clinical data from two programs will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO), being held from May 29 - June 2, 2015 in Chicago, IL.

Curis' study investigators will present data from the Phase 1 study of CUDC-907, Curis' proprietary oral, dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor that is being studied in the ongoing expansion stage of a Phase 1 trial, with a focus on patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA recently granted Orphan Drug Designation to CUDC-907 for the treatment of DLBCL. Curis is also conducting a separate Phase 1 trial to investigate CUDC-907 in patients with advanced solid tumors, including those with advanced hormone receptor positive breast cancer or with NUT midline carcinoma.

In addition, data will be presented from clinical studies of Erivedge®, a first-in-class hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.

Additional information on the presentations can be found below and abstracts can be accessed at www.asco.org.

CUDC-907 Poster Presentation:

Date/Time:	**Sunday, May 31, 2015, 8:00 AM - 11:30 AM**
Abstract Number:	8537
Presentation Title:	*Phase 1 first-in-human trial of oral*CUDC-907*, a dual inhibitor of PI3K and HDAC, in patients with refractory/relapsed lymphoma or multiple myeloma.*
Presenter:	Jesus G. Berdeja, MD

Erivedge Poster Presentations:

Date/Time:	**Monday, June 1, 2015, 1:15 PM - 4:45 PM**
Abstract Number:	9022
Presentation Title:	*Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study.*
Presenter:	Simon S. Yoo, MD

Date/Time:	**Monday, June 1, 2015, 1:15 PM - 4:45 PM**
Abstract Number:	9023
Presentation Title:	*The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib.*
Presenter:	Mario E. Lacouture, MD

Date/Time:	**Monday, June 1, 2015, 1:15 PM - 4:45 PM**
Abstract Number:	9024
Presentation Title:	*Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.*
Presenter:	Reinhard Dummer, MD

About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90 inhibitor. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis expects to exercise options to exclusively license oral small molecules antagonists of PDL-1 and IRAK4. Curis is also party to a collaboration agreement with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Senior Vice President,

Corporate Strategy and Investor Relations

Curis, Inc.

617-503-6605

mmohindru@curis.com

Media Contact

David Schull

Russo Partners

(212) 845-4271

david.schull@russopartnersllc.com
